BioSpace News Archive

The Federal Aviation Administration indicated that charter flights began flying Pfizer-BioNTech’s COVID-19 vaccine from Belgium to the U.S. on November 27 in the first “mass air shipment.”

California-based Grail aims to alter the devastating trajectory of cancer mortality with the addition of one simple blood test.

Sage and Biogen forged the deal to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder, postpartum depression and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.

Venture capital investment firm GV, formerly Google Ventures, led the Series A financing round for the company. Other investors contributed to the round but have decided to remain anonymous.

Moderna announced that it plans to submit its request to the U.S. Food and Drug Administration for an Emergency Use Authorization for its COVID-19 vaccine, mRNA-1273.

Another clinical study could confirm the 90% efficacy data that stemmed from accidental use of a half-dose in an arm of its Phase III trial.

The FDA approval was based on results from the largest studies conducted to date in obesity associated with POMC, PCSK1 or LEPR deficiency.

Over a decade of research and billions of dollars have been poured into Alzheimer’s disease treatment. Experts are hopeful we could finally find a cure.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that the company’s Marketing Authorization Application (MAA) for its investigational medicine, maralixibat, for the treatment of patients with progressive familial intrahepatic cholestasis type 2 (PFIC2),

Carestream Health showcased its expertise in medical imaging across an array of clinical specialties at the virtual meeting of the Radiological Society of North America.